Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

06/28/2018 | 05:11am EST
FILE PHOTO: The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc, failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favor, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal.

The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

The 130 member-group formed by ex-Takeda employees told Reuters earlier this month it did not expect its proposal to pass on Thursday.

It said it is working to persuade a third of shareholders to vote against a company proposal at a Takeda shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself.

Thursday's proposal reflected concerns among some investors about the attempt by Chief Executive Christophe Weber - the company's first foreign head - to clinch the largest-ever overseas purchase by a Japanese company.

The move would turn Takeda into one of the world's most indebted drugmakers, though Weber has insisted he can deliver savings to make the deal a big winner for shareholders.

Shares in Takeda and Shire both gained more than 2 percent following the AGM.

Takeda's shares are nevertheless down 18 percent at 4,524 yen since the company first said at the end of March it was considering bidding for Shire.

With uncertainty over whether the acquisition will be approved by shareholders and given concern over the size of the deal, "investors are taking a wait-and-see stance" toward Takeda stock, UBS analyst Atsushi Seki wrote in a note to clients last week.

In the note, UBS upgraded its recommendation on Takeda stock to "buy" from "neutral" and raised its price target to 6,700 yen. It also said a survey of 60 Japanese investors found 31 percent viewed the Shire deal negatively.

Proxy advisor Institutional Shareholder Services (ISS) recommended voting against Thursday's proposal, saying that while its "proponents raise legitimate concerns about the planned acquisition of Shire" there was an "absence of apparent grounds to cast doubt over the board's objectivity or competence".

(Reporting by Sam Nussey and Ritsuko Shimizu; Additional reporting by Ben Hirschler; Editing by Christopher Cushing)

By Sam Nussey


© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
ISS A/S -0.39% 102 Delayed Quote.-2.94%
JUST GROUP PLC -2.80% 72.0773 Delayed Quote.6.08%
NEXT PLC -2.26% 7860 Delayed Quote.13.41%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 3.54% 3714 End-of-day quote.-1.09%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.17% 104.32 Delayed Quote.0.40%
WILL GROUP, INC. 4.97% 1057 End-of-day quote.5.07%
WORLD CO., LTD. -0.91% 1307 End-of-day quote.4.31%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
01/27TAKEDA PHARMACEUTICAL : Achieved Carbon Neutrality in 2020
PU
01/26TAKEDA PHARMACEUTICAL : Achieves Industry-Leading Positions in 2021 Access to Me..
BU
01/26Japan shares end lower on vaccine delay, caution ahead of earnings season
RE
01/25Japan stocks slip on vaccine worries, profit-taking ahead of earnings
RE
01/25TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
AQ
01/25Japanese shares gain tracking U.S. futures; tech and pharma stocks boost
RE
01/24Japanese shares track U.S. futures higher, tech leads gains
RE
01/24TAKEDA PHARMACEUTICAL : Named Global Top Employer for Fourth Consecutive Year
PU
01/22TAKEDA PHARMACEUTICAL : Manufacturing and Marketing Approval Received in Japan f..
PU
01/21TAKEDA PHARMACEUTICAL : Starts Clinical Trial of Moderna's COVID-19 Vaccine Cand..
MT
More news
Financials
Sales 2021 3 233 B 30 972 M 30 972 M
Net income 2021 202 B 1 937 M 1 937 M
Net Debt 2021 3 840 B 36 795 M 36 795 M
P/E ratio 2021 35,5x
Yield 2021 4,78%
Capitalization 5 889 B 56 589 M 56 424 M
EV / Sales 2021 3,01x
EV / Sales 2022 2,82x
Nbr of Employees 47 495
Free-Float 99,1%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 150,00 JPY
Last Close Price 3 767,00 JPY
Spread / Highest target 72,6%
Spread / Average Target 36,7%
Spread / Lowest Target 8,84%
EPS Revisions
Managers and Directors
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.09%56 589
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
PFIZER INC.-1.55%201 436
MERCK & CO., INC.-5.78%194 990